That can introduce variability such as: Mislabeling Contamination Inconsistent dosing Unknown impurities Side effects: what we can responsibly say Because robust human safety data are limited, it's hard to give a definitive side-effect profile with meaningful incidence rates
In a clinical environment, safety protocols are non-negotiable
If you want to own a piece of Smartweave and participate directly in what were building, our WeFunder page is now live (link in comments)
Simple calculations help maintain consistent concentration for research applications
TB-500 and Neurological Recovery Research In a rat embolic stroke model, administration of T4 at 24 hours after middle cerebral artery occlusion and every 3 days for 4 additional doses produced significant improvement in functional neurological outcome with evidence of axonal remodelling at the ischaemic boundary, increased oligodendrocyte precursor cells in the SVZ, striatum, and corpus callosum, and increased mature oligodendrocytes suggesting a mechanism involving axonal remodelling rather than direct neuroprotection